Aktuelle Studien zum Nierenzellkarzinom
Sie befinden sich hier:
|
Studientitel |
Status |
Seit |
Medikation |
|
MK-6482-022 A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy |
Aktiv |
01/2023 Rekrutierung aktiv |
Belzutifan (HIF-2-alpha Inhibitor, MK-6482) plus Pembrolizumab vs. Placebo plus Pembrolizumab |
|
MK-6482-012 An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as first line treatment in Participants with Advanced ccRCC |
Aktiv |
07/2022 Rekrutierung aktiv |
Arm 1: MK-6482 120 mg PO QD + Pembrolizumab 400 mg IV Q6W + Lenvatinib 20mg PO QD Arm 2: MK-1308A= MK-1308 25mg/MK-3475 400mg IV Q 6W + Lenvatinib 20mg PO QD Arm 3: Pembrolizumab 400mg IV Q6W + Lenvatinib 20mg PO QD |
|
MK-6482-011: An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy |
Aktiv |
08/2021 Rekrutierung aktiv |
Belzutifan (HIF-2-alpha Inhibitor,MK-6482) plus Lenvatinib vs Cabozantinib |
|
F-FR-60000-023 Cabopoint A Phase II, multicentre, open-label study of CABOZANTINIB as 2nd line treatment in subjects with unesectable, locally advanced or metastatic Renal Cell Carcinoma with a clear-cell component who progressed after 1st line treatment with checkpointinhibitors |
Aktiv |
07/2021 Rekrutierung aktiv |
Cabozantinib |
|
Pazoreal Nicht-interventionelle Studie zur Untersuchung der Effizienz und Sicherheit von PAZOpanib und Everolimus im REAL-Life Setting bei fortgeschrittenem Nierenzellkarzinom in einer wachsenden Therapieumgebung |
Aktiv |
27.09.2016 Rekrutierung aktiv |
Pazopanib und Everolimus |
|
MK-6482-005 An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Partici-pants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies |
Aktiv |
Rekrutierung abgeschlossen |
MK-6482 (Belzutifan, HIF-2 alpha Inhibitor, vs. Everolimus) |
|
KEYNOTE-564: Eine Phase III, randomisierte, doppel-blinde Plazebo-kontrollierte klinische Studie über Pembrolizumab (MK-3475) als adjuvante Monotherapie in der Behandlung von Nierenzellkarzinom nach Nephrektomie. |
Aktiv |
Rekrutierung abgeschlossen |
Pembrolizumab |
|
EISAI E7080-G000-307 A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma |
Aktiv |
Rekrutierung abgeschlossen |
Lenvatinib + Everolimus oder Pembrolizumab vs. Sunitinib |
|
Ansprechpartner |
|||
|
Sektionsleiterin Prof. Dr. M. De Santis, OÄ Dr. U. Steiner, A. Biniszkiewicz, Tel.: 030-450 615092, Fax: 030-450 7515927 |